

Freedom of Information request 162-22

Request

Seeking to understand initiation of patient treatment with Nivolumab, and some additional products in different types of cancer. We would greatly appreciate if you could answer the following questions:

Q1. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma?

- Nivolumab (monotherapy)
- Nivolumab AND Ipilimumab (combination)

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q2. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?

- Nivolumab (monotherapy)
- Nivolumab + Ipilimumab
- Nivolumab + Cabozantinib
- Avelumab + Axitinib

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q3. In the past 3 months, how many patients have been initiated* on the following agents for treatment for Advanced/Metastatic Oesophageal Cancer:

- Nivolumab (monotherapy)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Response

1. In the last 3 months the following number of patients have been initiated on the following agents for treatment for melanoma:

- Nivolumab (monotherapy) <5
- Nivolumab AND Ipilimumab (combination) 0

2. In the last 3 months the following number of patients have been initiated on following agents for treatment for Renal Cell Carcinoma:

- Nivolumab (monotherapy) <5
- Nivolumab + Ipilimumab 0
- Nivolumab + Cabozantinib 0
- Avelumab + Axitinib 0

3. In the last 3 months the following number of patients have been initiated on the following agents for treatment for Advanced/Metastatic Oesophageal Cancer:

- | | |
|---|---|
| • Nivolumab (monotherapy) | 0 |
| • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) | 0 |

As NHS Borders is such a small Board and the number of patients initiated is very small, to provide further details could allow individuals to be identified and we would be in breach of the Data Protection Act 2018. We are therefore withholding all other data under Section 38(1)(b) of the Freedom of Information (Scotland) Act 2002. This is in accordance with the Code of Practice for Official Statistics which states that any number that is less than five; actual numbers and potentially identifiable information is withheld to help maintain patient confidentiality due to potential risk of disclosure. Further information is available in the ISD Statistical Disclosure Control Protocol.

If you are not satisfied with the way your request has been handled or the decision given, you may ask NHS Borders to review its actions and the decision. If you would like to request a review please apply in writing to, Freedom of Information Review, NHS Borders, Room 2EC3, Education Centre, Borders General Hospital, Melrose, TD6 9BS or foi.enquiries@borders.scot.nhs.uk.

The request for a review should include your name and address for correspondence, the request for information to which the request relates and the issue which you wish to be reviewed. Please state the reference number **162-22** on this request. Your request should be made within 40 working days from receipt of this letter.

If following this review, you remain dissatisfied with the outcome, you may appeal to the Scottish Information Commissioner and request an investigation of your complaint. Your request to the Scottish Information Commissioner should be in writing (or other permanent form), stating your name and an address for correspondence. You should provide the details of the request and your reasons for dissatisfaction with both the original response by NHS Borders and your reasons for dissatisfaction with the outcome of the internal review. Your application for an investigation by the Scottish Information Commissioner must be made within six months of your receipt of the response with which you are dissatisfied. The address for the Office of the Scottish Information Commissioner is, Office of the Scottish Information Commissioner, Kinburn Castle, Doubledykes Road, St Andrews, Fife.